To elucidate the mechanism(s) of influenza viral RNA replication, we have developed an in vitro system in which the templates for viral RNA replication as well as the viral messenger RNAs (mRNAs) are synthesized. Because the synthesis of both the viral mRNAs and the template RNAs occurs in the nucleus of infected cells, we determined whether infected cell nuclei are active in the synthesis of these two types of transcripts in vitro. Nuclei isolated as early as 1-2 hr after infection catalyze the in vitro synthesis of both the viral mRNAs and template RNAs. The time course of appearance of these activities indicates that they most likely represent the transcriptional complexes functioning in vivo. Template RNA synthesis catalyzed by the nuclei in vitro is independent of concomitant protein synthesis; rather, it utilizes preformed proteins present in the nuclear preparations. This protein pool can be depleted by treating the infected cells with a protein synthesis inhibitor prior to the isolation of the nuclei, thereby rendering the nuclei inactive in template RNA synthesis in vitro. This activity can be restored by the addition of infected cell cytoplasmic extracts or of the high-speed supernatant fraction from these extracts. These results indicate that the cytoplasmic fraction from infected cells enables the viral transcription complex to continue transcription past the site at which termination occurs during viral mRNA synthesis and also suggest that this fraction enables the transcription complex to initiate transcription without the capped primer used in viral mRNA synthesis.
ABSTRACT
To elucidate the mechanism(s) of influenza viral RNA replication, we have developed an in vitro system in which the templates for viral RNA replication as well as the viral messenger RNAs (mRNAs) are synthesized. Because the synthesis of both the viral mRNAs and the template RNAs occurs in the nucleus of infected cells, we determined whether infected cell nuclei are active in the synthesis of these two types of transcripts in vitro. Nuclei isolated as early as 1-2 hr after infection catalyze the in vitro synthesis of both the viral mRNAs and template RNAs. The time course of appearance of these activities indicates that they most likely represent the transcriptional complexes functioning in vivo. Template RNA synthesis catalyzed by the nuclei in vitro is independent of concomitant protein synthesis; rather, it utilizes preformed proteins present in the nuclear preparations. This protein pool can be depleted by treating the infected cells with a protein synthesis inhibitor prior to the isolation of the nuclei, thereby rendering the nuclei inactive in template RNA synthesis in vitro. This activity can be restored by the addition of infected cell cytoplasmic extracts or of the high-speed supernatant fraction from these extracts. These results indicate that the cytoplasmic fraction from infected cells enables the viral transcription complex to continue transcription past the site at which termination occurs during viral mRNA synthesis and also suggest that this fraction enables the transcription complex to initiate transcription without the capped primer used in viral mRNA synthesis.
Influenza virus employs a unique mechanism for the synthesis of its viral mRNA. A viral endonuclease cleaves 5'-terminal fragments from heterologous capped (m7GpppNm-containing) RNAs, and these capped fragments are used as primers to initiate viral mRNA synthesis (1) (2) (3) (4) (5) (6) . The viral mRNA chains are then elongated until a site of termination and polyadenylate [poly(A)] addition is reached 17-22 nucleotides from the 5' ends of the virion RNA (vRNA) templates (7) (8) (9) . The mechanism of viral mRNA synthesis and the specific roles of viral proteins in this process were elucidated primarily by analyses of the in vitro reaction catalyzed by virion nucleocapsids (4, 6, (10) (11) (12) (13) .
Much less is known about influenza vRNA replication. The presumed first step in replication is the synthesis of fulllength transcripts of the vRNAs. Such transcripts, or template RNAs, have been identified in infected cells (7, 14, 15) , but they have not been synthesized in vitro. These template RNAs, unlike the viral mRNAs, are initiated without a primer and contain a copy of the last 17-22 nucleotides at the 5' ends of the vRNAs (7, 15) . The template RNAs are not polyadenylylated and require ongoing protein synthesis, presumably virus-encoded, for their synthesis (15, 16) .
This publication reports the development of an in vitro system in which the synthesis of both template RNA and viral mRNA occurs. This in vitro system should allow the determination of the mechanism of the switch from viral mRNA to template RNA synthesis, the first step in influenza vRNA replication.
MATERIALS AND METHODS
Preparation of Extracts. BHK-21 hamster cells were grown and infected with WSN influenza virus as described (14) . At the time points of infection indicated, the cells were scraped in RSB (10 mM Tris HCl, pH 7.5/10 mM KCI/1.5 mM MgCl2), collected by centrifugation at 250 x g for 5 min, and resuspended in 10 vol of RSB. After swelling on ice for 10 min, the cells were subjected to 35 strokes in a Wheaton homogenizer with a type A pestle. The extracts were centrifuged at 250 x g for 5 min. The pellet, which contained the nuclei was washed with 10 vol of RSB, repelleted, and resuspended in an equal volume of a buffer containing 25% (vol/ vol) glycerol, 5 mM Mg(OAc)2, 0.1 mM EDTA, 5 mM 2-mercaptoethanol, and 50 mM Hepes/KOH, pH 7.5. The concentration of nuclei in each sample was approximately 108 per ml. The first supernatant constituted the cytoplasmic extract, which, where indicated, was centrifuged for 1.5 hr at 60,000 rpm in the Beckman SW 65 rotor to prepare a cytoplasmic extract free of viral nucleocapsids (high-speed supernatant). In one experiment, the infected cells were not fractionated into cytoplasm and nuclei, but instead were made permeable to triphosphates by treatment with lysolecithin (17 thesis was examined, the poly(A)+ RNA was incubated with RNase H dnd pligo(dT) to remove poly(A), and the RNA was analyzed on 3.5% acrylamide/8 M urea gels (18) . When the synthesis of both template RNAs and viral mRNAs was examined, two types of analyses were used. In one, the poly(A)+ and poly(A)-RNAs after heat denaturation were each annealed with an excess (3 ug) of unlabeled vRNA in 55% (vol/vol) formamide, and after INase T2 digestion, the virus-specific double-stranded RNAs were analyzed on 3.5% nondenaturing acrylamide gels (18) . Alternatively, the poly(A)' and poly(A)-RNAs were each annealed with an excess (0.5 ,g) of a vRNA sense DNA clone of the NS segment in M13 phage. The mixture of RNA and NS M13 DNA in 15 Al of 0.7 M NaCl/50 mM Hepes/KOH, pH 7/1 mM EDTA was heated at 80°C for 10 min and then hybridized at 50°C for 16 hr. After precipitation with qthanol, the mixture was digested with RNase T2, extracted with phenol, and, after adjustment to 0.2 M NaCl/10 mM Hepes, pH 7.5/1 mM EDTA was filtered through nitrocellulose filters to select RNADNA hybrids (19) . The RNA was eluted by heating at 100°C for 5 min in 300 ,il of 2 mM EDTA and analyzed by electrophoresis on a 3.5% acrylamide gel containing 8 M urea.
Materials. [a-32P]UTP was purchased from Amersham.
AlMV RNA 4 was kindly provided by John Bol, and its cap 0 structure was converted to a cap 1 structure by using a vaccinia virus enzyme (2, 4) . AlMV RNA 4 containing a labeled cap 1 structure was prepared as described previously (2, 4 (14, 20) , we determined whether infected cell nuclei are active in the synthesis of these two types of transcripts in vitro. Preparations of infected cell nuclei that exhibited the highest activity for viral RNA transcription in vitro were obtained by avoiding the use of detergents. The nuclear pellet obtained after homogenization of the cells in hypotonic buffer (RSB) was washed with a large volume of this buffer to remove trapped cytoplasmic components. Phase-contrast microscopy indicated that these nuclei were free of essentially all debris, presumably cytoplasmic in origin, but that some of the nuclei contained small fragments of cytoplasmic material attached to the nuclear membrane. This low level of cytoplasmic contamination was tolerated to preserve optimal transcription activity.
To determine whether these infected cell nuclei were capable of synthesizing the viral mRNAs, nuclei isolated at 3 hr after infection were incubated with four nucleoside triphosphates (one labeled) under essentially the conditions employed for the virion-associated transcriptase, but in the absence of an added capped primer RNA. The poly(A)+ RNA products (after enzymatic deadenylylation) were analyzed by gel electrophoresis. As shown in Fig. 1 mRNAs (2, 3, 7) . The resulting hybrids are 17-22 nucleotides shorter than the hybrids containing the template RNAs. Consequently, particularly for the hybrids containing the smaller vRNAs, the vRNA-viral mRNA hybrids can be resolved from the vRNA-template RNA hybrids by gel electrophoresis (7, 14) .
Nuclei isolated at 2 hr after infection catalyze the synthesis of template RNAs (Fig. 2, lanes 2 and 4) . The template RNAs copied off the NS, M, and NA vRNAs are evident as major species in the poly(A)-fraction (shown by the arrows). A small amount of activity was detected in nuclei as early as 1 hr after infection (lane 10). This nuclear activity reached its maximum at 3-4 hr (lanes 6 and 8) and then declined (data not shown). Only very low activity was detected in the cytoplasmic fraction (see later).
This assay also detects the viral mRNA synthesized by the nuclei. The mRNA was found primarily in the poly(A)+ fraction (Fig. 2, odd-numbered lanes) , though a fraction of it was also detected in the poly(A)-fraction (even-numbered lanes). Because of the sensitivity of this assay, the synthesis of poly(A)+ viral mRNA was detected at low levels with nuclei isolated at 1 hr after infection (lane 9), and the synthesis of the P mRNAs was clearly seen (e.g., lane 11). The time courses of appearance of the two virus-specific activities were similar, though not identical. The ratio of template 1-4, 11 , and 12), 3 hr (lanes 5 and 6), and 4 hr (lanes 7 and 8) after infection were incubated with four ribonucleoside triphosphates under the conditions that allow concomitant protein synthesis as described in the text. The RNA products were fractionated by oligo(dT)-cellulose chromatography into poly(A)+ (odd-numbered lanes) and poly(A)-(even-numbered lanes) fractions. Both the poly(A)+ and poly(A)-RNAs were annealed with an excess of vRNA, and the hybrids were digested with RNase T2 and analyzed by gel electrophoresis. The arrows indicate hybrids between vRNA and template RNAs. Lanes 1 and 2 show a longer exposure of lanes 3 and 4 to x-ray film, and lanes 11 and 12 show a very long exposure of lanes 3 and 4 to x-ray film compared to a similar exposure of the gel analysis of the RNAs synthesized by nuclei isolated at 1 hr after infection (lanes 9 and 10). The same relative amounts of viral mRNA and template RNA synthesis at the different times of infection were observed in assays containing 10 ,ul of nuclei.
RNA to mRNA molecules synthesized by the nuclei increased from 2 to 4 hr after infection, and the nuclei isolated at 4 hr synthesized more template RNAs than viral mRNAs.
To determine whether concomitant protein synthesis was actually required for the synthesis of template RNAs in vitro, we tested the effect of inhibitors of protein synthesis on template RNA synthesis (Fig. 3A) . Neither cycloheximide nor anisomycin (not shown) inhibited either viral mRNA or template RNA synthesis catalyzed by the nuclear preparations (compare lanes 3 and 4 to lanes 1 and 2 in Fig. 3A) . This lack of dependence on ongoing protein synthesis was also observed when unfractionated infected cells (permeabilized with lysolecithin) were used to catalyze template RNA synthesis (data not shown).
These results suggest that influenza virus-infected cells contain a pool of protein(s) that is capable of supporting the synthesis of template RNAs in vitro and that a sufficient amount of these proteins remains associated with the nuclear preparations. To remove these proteins, we treated the infected cells with anisomycin at 2.5 hr prior to the isolation of the nuclei at 3 hr. Nuclei isolated from these cells do not catalyze template RNA synthesis in vitro (Fig. 3B, lane 4) , whereas they retain their activity in viral mRNA synthesis (lane 3).
Reconstituted System for Template RNA Synthesis. A likely explanation for the background seen in the analyses of Figs. (20 ,ul) isolated at 3 hr after infection were incubated in vitro under the transcription conditions that allow concomitant protein synthesis in the absence (lanes 1 and 2) or presence (lanes 3 and 4) of cycloheximide at 100 ,g/ml.
(B) One set of cells was treated at 2.5 hr after infection with 100 /AM anisomycin ( lanes 3 and 4) , and another set of infected cells was not treated (lanes 1 and 2) . Both sets of cells were collected at 3 hr after infection, and the isolated nuclei (20 ,ul) were incubated under the conditions allowing concomitant protein synthesis. In both A and B, lanes 1 and 3 are poly(A)+ and lanes 2 and 4 are poly(A)-RNAs. These RNAs were analyzed as described for Fig. 2 Using this assay, we determined whether we could restore the activity for template RNA synthesis to the nuclei from anisomycin-treated cells. We added to these nuclei either the cytoplasmic extract from infected cells (3 hr after infection) or the fraction prepared by high-speed centrifugation of this extract. The cytoplasmic extract effectively restored the activity for template RNA synthesis (Fig. 4 , compare lanes 4 and 5). The amount of template RNA synthesizing activity in this reconstituted system was much higher than that seen in the cytoplasmic extract alone (compare lanes 5 and 5a to lanes 7 and 7a). In addition, the high-speed supernatant fraction from the cytoplasmic extract, which contains no detectable template synthesizing activity by itself (lanes 8 and 8a) , restores template RNA synthesizing activity to the nuclei (lanes 6 and 6a). Anisomycin had no effect on template RNA synthesis in this reconstituted system, and cytoplasmic extracts from uninfected cells did not restore activity (data not shown).
DISCUSSION
Nuclei isolated from influenza virus-infected cells as early as 1-2 hr after infection catalyze the in vitro synthesis of both viral mRNAs and template RNAs. These nuclear activities increase until about 3-4 hr after infection. Previous experiments have established that both the viral mRNAs and template RNAs are synthesized in the nucleus in vivo (14, 20) and that most viral RNA transcription occurs during the first 4 hr of infection (7, 16, 21) . Consequently, the nuclear activities detected in the present study likely represent the transcriptional complexes responsible for viral mRNA and template RNA synthesis in vivo.
Unlike the virion-associated transcriptase, the nuclear transcription complexes synthesizing viral mRNAs are active in the absence of an exogenous capped RNA primer. This is not due to the concomitant synthesis of capped RNA primers by RNA polymerase II, as a-amanitin does not inhibit viral mRNA synthesis catalyzed by the nuclei. Rather, the observed in vitro viral mRNA synthesis can be explained by (i) in vitro elongation of mRNA chains initiated in vivo or (ii) initiation by endogenous capped RNAs in vitro followed by elongation. We could not distinguish between these two possibilities, but we showed that some initiation of viral mRNA chains occurred after addition of exogenous capped AIMV RNA 4. The amount of chain initiation, however, was much less than that occurring with the virion-associated transcriptase, as viral mRNA synthesis was stimulated only 2-to 5-fold by AIMV RNA 4, as compared to the almost 100-fold stimulation obtained with the virion-associated transcriptase (1, 6) . This suggests that endogenous capped RNA primers are present in the nuclei in amounts sufficient for a sizeable proportion of the viral transcription complexes and/or that only some of these nuclear complexes are capable of initiating viral mRNA chains in response to an added primer RNA.
The infected cell nuclei exhibited a relatively high activity for template RNA synthesis in vitro. In fact, some nuclear preparations (e.g., the 4-hr sample shown in Fig. 2 ) synthesized more template RNA than viral mRNA. In contrast, template RNA synthesis in the infected cell is only about 5% of viral'mRNA synthesis (7, 14) . In vitro and in vivo template RNA synthesis also differ in their need for concomitant protein synthesis. Protein synthesis inhibitors block template RNA synthesis in vivo (7, 16) , but not in vitro, catalyzed by either nuclei or lysolecithin-permeabilized whole cells (present study). Thus, the infected cells contain a pool of protein(s) sufficient for template RNA synthesis in vitro, whereas these protein(s) are apparently rate-limiting for this synthesis in vivo. This may explain why template RNA synthesis (relative to viral mRNA synthesis) is higher in vitro than in vivo.
The existence of a pool of soluble protein(s) needed for template RNA synthesis in infected cell extracts enabled us to establish a reconstituted system that catalyzes template RNA synthesis in vitro. This protein pool can be depleted by treating infected cells with a protein synthesis inhibitor prior to isolation of the nuclei, and as a consequence the viral transcriptase complexes in the nuclei are rendered inactive in template RNA synthesis in vitro. However, they regain this synthetic capacity when supplemented with the cytoplasmic extract from infected cells or its high-speed supernatant frac- to continue copying the vRNA template past the site at which termination occurs during viral mRNA synthesis (17-22 nucleotides from the 5' ends of the vRNAs). At the mRNA termination site on the vRNA templates, there is a tract of 5-7 uridine residues (22, 23) , and the available evidence suggests that during viral mRNA synthesis "stuttering" or reiterative copying of these uridine tracts occurs, resulting in poly(A) synthesis and the termination of transcription of the ensuing 5'-terminal vRNA sequences (9) . Factors present in the cytoplasmic extract of infected cells clearly inhibit this "stuttering" and termination step. A similar type of antitermination may also occur during the switch from mRNA to template RNA synthesis with other negativestrand RNA viruses, for example, with vesicular stomatitis virus (VSV), in which an antitermination mechanism may account for the switch from the synthesis of multiple mRNAs to a single full-length template RNA (24) . In fact, a reconstituted system capable of antitermination in vitro has recently been described for VSV (25) (26) (27) . Template RNA synthesis with influenza virus, but not with VSV, has an added complication in that it requires a change from the primer RNA-dependent initiation occurring during viral mRNA synthesis to a primer-independent initiation. The cytoplasmic factors from influenza virus-infected cells also probably confer the capability for primer-independent initiation on the viral transcriptase complexes in the nuclei. As verification, however, it will be necessary to establish that the template RNAs synthesized in vitro contain labeled di-or triphosphorylated 5' termini. These experiments will be feasible when the efficiency of template RNA synthesis in the reconstituted system is increased 10-fold or more.
On the basis of experiments using the virion transcriptase, the roles of the three influenza virus P proteins (PB1, PB2, and PA) in capped RNA-primed viral mRNA synthesis have been at least partially delineated. PB2 binds the cap of heterologous RNAs, which are cleaved to generate capped primer fragments (10) (11) (12) (13) . PB1 adds the initial nucleotide to this primer fragment and then catalyzes each subsequent nucleotide addition (10-13) but apparently cannot initiate chains. The three P proteins as a complex move down from the 3' ends of the vRNA templates until the site of poly(A) addition and chain termination is reached (13) . The inhibition of this "stuttering" and termination step by the cytoplasmic factors from infected cells most likely results from modification of one or more of the three P proteins and/or by the addition of one or more virus-encoded proteins to the P protein complex. Similarly, it is likely that the P protein complex would have to be altered to allow initiation of chains without a primer. Another important question to be addressed is whether the P protein complexes associated with the nucleocapsids in the nuclei of infected cells are identical with the P protein complexes associated with the virion nucleocapsids. We have found that the addition of infected cell cytoplasmic fractions to virion nucleocapsids results in template RNAsynthesizing activity in some, but not all, experiments (data not shown), suggesting that with virion nucleocapsids additional factors are required for the switch to template RNA synthesis. It should be possible to resolve this issue and to determine the mechanism of the switch from viral mRNA synthesis to template RNA synthesis-the first step in vRNA replication-by the identification and purification of the cytoplasmic factors that confer template RNA-synthesizing activity to nuclear and virion nucleocapsids.
